Northwest Biotherapeutics | NWBO - Selling And Administration Expenses


Northwest Biotherapeutics reported $7.03M in Selling and Administration Expenses for its fiscal quarter ending in September of 2023.





Selling And Administration Expenses Change Date
Agenus USD 23.6M 448K Sep/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Celldex Therapeutics USD 6.63M 546K Sep/2025
Eisai JPY 111.72B 7.86B Dec/2025
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
Merck USD 2.85B 215M Dec/2025
Northwest Biotherapeutics USD 7.03M 534K Sep/2023
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025